Skip to main content
. 2019 Nov 22;25(12):1343–1352. doi: 10.1111/cns.13260

Figure 4.

Figure 4

RSG drives anti‐inflammatory microglial polarization in delayed tPA treatment after stroke. A, Gating strategy for CD11b + CD45int cells in ischemic brain. B, Representative histogram of CD86 + microglia in ischemic brain 1 day in isotype, tPA, tPA + RSG groups (n = 6 per group). C, Representative histogram of CD206 + microglia in ischemic brain 1 day in isotype, tPA, tPA + RSG groups (n = 6 per group). D, Immunostaining of iNOS and Iba‐1 in brain sections 1 day after MCAO from mice treated with tPA or RSG + tPA. Scale bar = 100μm. E, Representative confocal images of CD206 and Iba‐1 double labeling in the brains obtained from tPA‐infused stroke mice with/without RSG. Scale bar = 100μm. F, Representative confocal images of Arg‐1 and Iba‐1 double immunostaining in the brains obtained from tPA‐infused stroke mice with/without RSG. Scale bar = 50μm. RSG, rosiglitazone; tPA, tissue plasminogen activator; MCAO, middle cerebral artery occlusion; iNOS, inducible nitric oxide synthase; Arg‐1, arginase 1; Iba‐1, ionized calcium‐binding adaptor molecule 1